Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
1(8%)
Results Posted
40%(2 trials)
Terminated
3(23%)

Phase Distribution

Ph not_applicable
2
15%
Ph phase_2
7
54%
Ph phase_3
4
31%

Phase Distribution

0

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
7(53.8%)
Phase 3Large-scale testing
4(30.8%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(5)
Terminated(3)
Other(4)

Detailed Status

Completed5
unknown4
Terminated3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
62.5%
Most Advanced
Phase 3

Trials by Phase

Phase 27 (53.8%)
Phase 34 (30.8%)
N/A2 (15.4%)

Trials by Status

active_not_recruiting18%
completed538%
terminated323%
unknown431%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials
NCT03297788Not Applicable

Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases

Completed
NCT04291092Phase 2

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Unknown
NCT01503827Not Applicable

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma

Unknown
NCT02447549Phase 2

Study of Tumour Focused Radiotherapy for Bladder Cancer

Active Not Recruiting
NCT02556593Phase 2

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Terminated
NCT00028925Phase 2

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Completed
NCT00977379Phase 2

A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis

Terminated
NCT02882984Phase 3

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

Unknown
NCT01887795Phase 3

Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study

Completed
NCT00030628Phase 3

Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Completed
NCT02338011Phase 2

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)

Unknown
NCT00570908Phase 2

Brain Mets - Capecitabine Plus Sunitinib and WBRT

Terminated
NCT00003563Phase 3

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

Completed

All 13 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
13